64cu-dota-daratumumab
mAbexperimentalADC
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Feb 21, 2018 (NCT03311828)
Timeline
Indications
Mechanism of action
- Lymphocyte differentiation antigen CD38Supplementation
CD38 supplementation
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 64-Copper
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05901545 | Phase 1 | Dec 31, 2023 | American Cancer Society, Inc., Vanderbilt University |
| NCT05892393 | Phase 1 | Jun 16, 2023 | National Cancer Institute (NCI), University of California, San Francisco |
| NCT05245006 | Phase 1 | Mar 18, 2022 | Department of Defense, Fortis Therapeutics, Inc., University of California, San Francisco |
| NCT04333537 | Phase 2/Phase 3 (Phase 3) | May 18, 2020 | National Cancer Institute (NCI), NRG Oncology |
| NCT03311828 | Phase 1 | Feb 21, 2018 | City of Hope National Medical Center |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2020 |
| University of California, San Francisco | Academic/Hospital | 2 | 2 | 1 | 2022 |
| American Cancer Society, Inc. | Academic/Hospital | 1 | 0 | 1 | 2023 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Department of Defense | Government | 1 | 0 | 1 | 2022 |
| Fortis Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2022 |
| NRG Oncology | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2023 |
8 organizations
Page 1 / 1